Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial, and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. In addition, Fusion is pursuing combination programs between RCs and DNA Damage Response Inhibitors (DDRis) and immune-oncology agents. Fusion has a fully operational Good Manufacturing Practice (GMP) compliant state-of-the-art radiopharmaceutical manufacturing facility to meet supply demand for Fusion's growing pipeline of RCs.
As a CMC Scientific Writer reporting into the Sr. Manager, Radiopharmaceutical CMC you will be involved in the authoring of CMC modules for Phase III studies through to marketing/commercialization. As part of Fusions radiopharmaceutical manufacturing department, the CMC Scientific Writer will support time critical CMC Regulatory submissions. This role will liaise with other CMC and non-CMC functions, draft needed regulatory content and collaborate in cross-functional teams.
This position is ideally based in Hamilton, ON, or Boston, MA. Some travel may be required to CDMO sites and/or to the Hamilton Headquarters.
Responsibilities:
Qualifications
Additional considerations:
Fusion Pharmaceuticals is an equal opportunity employer that is committed to inclusive, barrier-free recruitment and selection processes, if contacted for an interview, please advise Human Resources if you require accommodation.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual, gender identity, national origin, disability, or status as a protected veteran.